ESMO 2023 | The role of monotherapy TKI’s in the treatment of patients with hepatocellular carcinoma

Stephen L. Chan, MBBS MRCP, FHKCP, FHKAM, FRCP, The Chinese University of Hong Kong, Hong Kong, China, discusses the validity of utilizing tyrosine kinase inhibitors (TKIs) to treat patients in first- and second-line settings for hepatocellular carcinoma (HCC), stressing that it is an important option for patients who are ineligible for immunotherapy or are refractory to first-line immunotherapies. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.